Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Oliver Weigert, Donna Neuberg et al.|The Lancet Oncology|2015Cited by 613
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C. Townsend, Michelle A. Kelliher, Mark A. Murakami et al.|Cancer Cell|2016Cited by 304
Targeting minimal residual disease: a path to cure?Marlise R. Luskin, David M. Weinstock, Mark A. Murakami et al.|Nature reviews. Cancer|2018Cited by 164
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y. Ng, Raphael Koch, Noriaki Yoshida et al.|Nature Communications|2018Cited by 114
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C. Townsend, Michelle A. Kelliher, Mark A. Murakami et al.|Cancer Cell|2016Cited by 78